AlzeCure Pharma AB has signed an out-licensing and collaboration agreement with Danish biotech company QuantumCell ApS for the global rights to its NeuroRestore platform, including its lead Alzheimer’s disease drug candidate, ACD856.
The deal could be worth more than $2.2 billion to AlzeCure, excluding royalty payments, and represents a major step forward for the Swedish biotechnology company’s central nervous system, or CNS, drug development portfolio. The agreement includes a total upfront payment of $12 million, with $5 million structured as a direct investment in AlzeCure at a 30% premium to the company’s average share price over the previous 10 trading days.
In addition to the upfront payment, AlzeCure is eligible to receive development and commercial milestone payments, along with tiered royalties ranging from single-digit to low double-digit percentages on future product sales. The transaction remains subject to customary closing conditions, including foreign direct investment approvals from Swedish and Danish authorities.
Under the agreement, QuantumCell will receive worldwide rights to develop, manufacture and commercialize NeuroRestore and ACD856. AlzeCure said the partnership could help accelerate the development of the platform across multiple neurological and psychiatric disorders, including Alzheimer’s disease, Parkinson’s disease and depression.
ACD856 is a small-molecule drug candidate designed to enhance signaling through nerve growth factor and brain-derived neurotrophic factor pathways. The therapy is described as a positive allosteric modulator of NGF/TrkA and BDNF/TrkB signaling, also known as a Trk-PAM mechanism.
These biological pathways are involved in neuron survival, communication, learning and memory. In preclinical studies, ACD856 has shown potential cognitive-enhancing, neuroprotective, anti-inflammatory and disease-modifying effects. AlzeCure said the drug candidate has also demonstrated antidepressant activity in preclinical models.
The company previously reported positive clinical results for ACD856, which is currently in clinical development. If successful, the drug could offer a new treatment approach for Alzheimer’s disease, where existing therapies often focus on slowing disease progression or managing symptoms rather than supporting neuronal communication and cognitive function.
Johan Sandin, chief scientific officer at AlzeCure Pharma, said the clinical and preclinical findings support the potential of ACD856 across a broad range of indications. He noted that the candidate’s cognitive, neuroprotective and antidepressant effects could make it a promising asset in CNS drug development.
Martin Jönsson, chief executive officer of AlzeCure Pharma, said the transaction validates the company’s ability to advance a first-in-class drug project from early discovery into clinical development. He added that the QuantumCell partnership could enable NeuroRestore assets to reach patients across multiple disease areas more quickly.
The agreement highlights continued investor and pharmaceutical industry interest in Alzheimer’s disease drug development and novel CNS therapies. As demand grows for treatments that can address cognitive decline, neurodegeneration and mental health disorders, partnerships involving innovative small-molecule drug candidates are becoming increasingly important in the precision neuroscience market.